XML 40 R27.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2018

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Schedule of intangible assets, excluding licenses

The following tables sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets, (excluding licenses) as of September 30, 2018 and December 31, 2017:

		September 30, 2018
		Gross Carrying Amount				Accumulated Amortization				Net Amount				Weighted- Average Remaining Amortization Period (yrs.)
Amortizable intangible assets:
OPERA^®software patent		$	31,951			$	(9,985	)		$	21,966				11
Development costs of corporate website			91,743				(91,743	)			—				n/a
Approved hormone therapy drug candidate patents			1,991,790				(247,536	)			1,744,254				14.25
Hormone therapy drug candidate patents (pending)			1,749,561				—				1,749,561				n/a
Non-amortizable intangible assets:
Multiple trademarks			255,749				—				255,749				indefinite
Total		$	4,120,794			$	(349,264	)		$	3,771,530

		December 31, 2017
		Gross Carrying Amount				Accumulated Amortization				Net Amount				Weighted- Average Remaining Amortization Period (yrs.)
Amortizable intangible assets:
OPERA^®software patent		$	31,951			$	(8,487	)		$	23,464				11.75
Development costs of corporate website			91,743				(91,743	)			—				n/a
Approved hormone therapy drug candidate patents			1,293,614				(171,911	)			1,121,703				15
Hormone therapy drug candidate patents (pending)			1,721,305				—				1,721,305				n/a
Non-amortizable intangible assets:
Multiple trademarks			233,275				—				233,275				indefinite
Total		$	3,371,888			$	(272,141	)		$	3,099,747

Schedule of estimated amortization expense

Estimated amortization expense for the next five years for the patent cost currently being amortized is as follows:

Year Ending December 31,				Estimated Amortization
	2018 (3 months)			$	31,100
	2019			$	124,400
	2020			$	124,400
	2021			$	124,400
	2022			$	124,400
	Thereafter			$	1,237,520